The Effect of Neurokinin1 Receptor Blockade on Territorial Aggression and in a Model of Violent Aggression


      Neurokinin1 (NK1) receptor blockers were recently proposed for the treatment of anxiety and depression. Disparate data suggest that NK1 receptors are also involved in the control of aggressiveness, but their role is poorly known.


      We evaluated the aggression-induced activation of NK1 neurons by double-labeling brain sections for NK1 receptors and c-Fos in two laboratory models of aggression. We also studied the effects of the NK1 antagonist L-703,606 in these models.


      Aggressive encounters activated a large number of NK1 receptor-expressing neurons in areas relevant for aggression control. The activation was aggression-specific, because the effects of psychosocial encounters (that allowed sensory but not physical contacts) were markedly weaker. In the medial amygdala, the activation of neurons expressing NK1 receptors showed a marked positive correlation with the occurrence of violent attacks. In resident/intruder conflicts, NK1 blockade lowered the number of hard bites, without affecting milder forms of attack. In the model of violent aggression, attacks on vulnerable body parts of opponents (the main indicators of violence in this model) were decreased to the levels seen in control subjects. Autonomic deficits seen in the model of violent aggression were also ameliorated. The effects of the compound were not secondary to changes in locomotion or in the behavior of intruders.


      Our data show that neurons expressing NK1 receptors are involved in the control of aggressiveness, especially in the expression of violent attacks. This suggests that NK1 antagonists—beyond anxiety and depression—might also be useful in the treatment of aggressiveness and violence.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Saffroy M.
        • Torrens Y.
        • Glowinski J.
        • Beaujouan J.C.
        Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: Comparison with NK1 and NK3 binding sites.
        Neuroscience. 2003; 116: 761-773
        • Tsuchida K.
        • Shigemoto R.
        • Yokota Y.
        • Nakanishi S.
        Tissue distribution and quantitation of the mRNAs for three rat tachykinin receptors.
        Eur J Biochem. 1990; 193: 751-757
        • Yip J.
        • Chahl L.A.
        Localization of tachykinin receptors and Fos-like immunoreactivity induced by substance P in guinea-pig brain.
        Clin Exp Pharmacol Physiol. 2000; 27: 943-946
        • Czeh B.
        • Fuchs E.
        • Simon M.
        NK1 receptor antagonists under investigation for the treatment of affective disorders.
        Expert Opin Investig Drugs. 2006; 15 (Review): 479-486
        • File S.E.
        NKP608, an NK1 receptor antagonist, has an anxiolytic action in the social interaction test in rats.
        Psychopharmacology (Berl). 2000; 152: 105-109
        • Rupniak N.M.
        • Carlson E.J.
        • Webb J.K.
        • Harrison T.
        • Porsolt R.D.
        • Roux S.
        • et al.
        Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs.
        Behav Pharmacol. 2001; 12: 497-508
        • Santarelli L.
        • Gobbi G.
        • Blier P.
        • Hen R.
        Behavioral and physiologic effects of genetic or pharmacologic inactivation of the substance P receptor (NK1).
        J Clin Psychiatry. 2002; 63 (Review): 11-17
        • Shaikh M.B.
        • Steinberg A.
        • Siegel A.
        Evidence that substance P is utilized in medial amygdaloid facilitation of defensive rage behavior in the cat.
        Brain Res. 1993; 625: 283-294
        • Yao R.
        • Rameshwar P.
        • Gregg T.
        • Siegel A.
        Co-localization of NK(1)-receptor mRNA with glutamate immunopositivity in cat hypothalamic neurons by the combination of in situ hybridization and immunohistochemistry.
        Brain Res Brain Res Protoc. 2001; 7: 154-161
        • De Felipe C.
        • Herrero J.F.
        • O’Brien J.A.
        • Palmer J.A.
        • Doyle C.A.
        • Smith A.J.
        • et al.
        Altered nociception, analgesia and aggression in mice lacking the receptor for substance P.
        Nature. 1998; 392: 394-397
        • Dolan M.
        • Anderson I.M.
        • Deakin J.F.
        Relationship between 5-HT function and impulsivity and aggression in male offenders with personality disorders.
        Br J Psychiatry. 2001; 178: 352-359
        • McBurnett K.
        • Lahey B.B.
        • Rathouz P.J.
        • Loeber R.
        Low salivary cortisol and persistent aggression in boys referred for disruptive behavior.
        Arch Gen Psychiatry. 2000; 57: 38-43
        • Virkkunen M.
        Urinary free cortisol secretion in habitually violent offenders.
        Acta Psychiatr Scand. 1985; 72: 40-44
        • Brennan P.A.
        • Raine A.
        • Schulsinger F.
        • Kirkegaard-Sorensen L.
        • Knop J.
        • Hutchings B.
        • et al.
        Psychophysiological protective factors for male subjects at high risk for criminal behavior.
        Am J Psychiatry. 1997; 154: 853-855
        • Raine A.
        Autonomic nervous system factors underlying disinhibited, antisocial, and violent behavior.
        Ann N Y Acad Sci. 1996; 794: 46-59
        • Raine A.
        Annotation: The role of prefrontal deficits, low autonomic arousal, and early health factors in the development of antisocial and aggressive behavior in children.
        J Child Psychol Psychiatry. 2002; 43: 417-434
        • Woodman D.
        • Hinton J.
        Catecholamine balance during stress anticipation: An abnormality in maximum security hospital patients.
        J Psychosom Res. 1978; 22: 477-483
        • Sareen J.
        • Stein M.B.
        • Cox B.J.
        • Hassard S.T.
        Understanding comorbidity of anxiety disorders with antisocial behavior: Findings from two large community surveys.
        J Nerv Ment Dis. 2004; 192: 178-186
        • Haller J.
        • van de Schraaf J.
        • Kruk M.R.
        Deviant forms of aggression in glucocorticoid hyporeactive rats: A model for ‘pathological’ aggression?.
        J Neuroendocrinol. 2001; 13: 102-107
        • Haller J.
        • Halasz J.
        • Mikics E.
        • Kruk M.R.
        Chronic glucocorticoid deficiency-induced abnormal aggression, autonomic hypoarousal, and social deficit in rats.
        J Neuroendocrinol. 2004; 16: 550-557
        • Haller J.
        • Mikics E.
        • Halasz J.
        • Toth M.
        Mechanisms differentiating normal from abnormal aggression: glucocorticoids and serotonin.
        Eur J Pharmacol. 2005; 526 (Review): 89-100
        • Haller J.
        • Kruk M.R.
        Normal and abnormal aggression: Human disorders and novel laboratory models.
        Neurosci Biobehav Rev. 2006; 30 (Review): 292-303
        • Fava M.
        Psychopharmacologic treatment of pathologic aggression.
        Psychiatr Clin North Am. 1997; 20: 427-451
        • Goedhard L.E.
        • Stolker J.J.
        • Heerdink E.R.
        • Nijman H.L.
        • Olivier B.
        • Egberts T.C.
        Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: A systematic review.
        J Clin Psychiatry. 2006; 67 (Review): 1013-1024
        • Herrmann N.
        Recommendations for the management of behavioral and psychological symptoms of dementia.
        Can J Neurol Sci. 2001; 28: S96-S107
        • Flint A.J.
        • van Reekum R.
        The pharmacologic treatment of Alzheimer’s disease: A guide for the general psychiatrist.
        Can J Psychiatry. 1998; 43: 689-697
        • Pabis D.J.
        • Stanislav S.W.
        Pharmacotherapy of aggressive behavior.
        Ann Pharmacother. 1996; 30: 278-287
        • Bassarath L.
        Medication strategies in childhood aggression.
        Can J Psychiatry. 2003; 48: 367-373
        • Coccaro E.F.
        • Kavoussi R.J.
        • Hauger R.L.
        Serotonin function and antiaggressive response to fluoxetine: A pilot study.
        Biol Psychiatry. 1997; 42: 546-552
        • Kutcher S.P.
        • Marton P.
        • Korenblum M.
        Relationship between psychiatric illness and conduct disorder in adolescents.
        Can J Psychiatry. 1989; 34: 526-529
        • Pine D.S.
        • Cohen E.
        Therapeutics of aggression in children.
        Paediatr Drugs. 1999; 1: 183-197
        • Cascieri M.A.
        • Ber E.
        • Fong T.M.
        • Sadowski S.
        • Bansal A.
        • Swain C.
        • et al.
        Characterization of the binding of a potent, selective, radioiodinated antagonist to the human neurokinin-1 receptor.
        Mol Pharmacol. 1992; 42: 458-463
        • Haddjeri N.
        • Blier P.
        Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission.
        Biol Psychiatry. 2001; 50: 191-199
        • MacLennan K.M.
        • Smith P.F.
        • Darlington C.L.
        Adrenalectomy-induced neuronal degeneration.
        Prog Neurobiol. 1998; 54: 481-498
        • Lammers J.H.
        • Kruk M.R.
        • Meelis W.
        • van der Poel A.M.
        Hypothalamic substrates for brain stimulation-induced attack, teeth-chattering and social grooming in the rat.
        Brain Res. 1988; 449: 311-327
        • Ogawa S.
        • Chester A.E.
        • Hewitt S.C.
        • Walker V.R.
        • Gustafsson J.A.
        • Smithies O.
        • et al.
        Abolition of male sexual behaviors in mice lacking estrogen receptors alpha and beta (alpha beta ERKO).
        Proc Natl Acad Sci U S A. 2000; 97: 14737-14741
        • Paxinos G.
        • Watson C.
        The Rat Brain in Stereotaxic Coordinates.
        4th ed. Academic Press, San Diego1998
        • Halasz J.
        • Liposits Zs
        • Kruk M.R.
        • Haller J.
        Neural background of glucocorticoid dysfunction-induced abnormal aggression in rats: Involvement of fear- and stress-related structures.
        Eur J Neurosci. 2002; 15: 561-569
        • Halasz J.
        • Tóth M.
        • Kalló I.
        • Liposits Z.
        • Haller J.
        The activation of prefrontal cortical neurons in aggression-A double labeling study.
        Behav Brain Res. 2006; 175: 166-175
        • Kruk M.R.
        Ethology and pharmacology of hypothalamic aggression in the rat.
        Neurosci Biobehav Rev. 1991; 15 (Review): 527-538
        • Hrabovszky E.
        • Halasz J.
        • Meelis W.
        • Kruk M.R.
        • Liposits Z.
        • Haller J.
        Neurochemical characterization of hypothalamic neurons involved in attack behavior: Glutamatergic dominance and co-expression of thyrotropin-releasing hormone in a subset of glutamatergic neurons.
        Neuroscience. 2005; 133: 657-666
        • Siegel A.
        • Roeling T.A.
        • Gregg T.R.
        • Kruk M.R.
        Neuropharmacology of brain-stimulation-evoked aggression.
        Neurosci Biobehav Rev. 1999; 23 (Review): 359-389
        • Fazel S.
        • Danesh J.
        Serious mental disorder in 23000 prisoners: A systematic review of 62 surveys.
        Lancet. 2002; 359 (Review): 545-550
        • Ekselius L.
        • Tillfors M.
        • Furmark T.
        • Fredrikson M.
        Personality disorders in the general population: DSM-IV and ICD_10 defined prevalence as related to sociodemographic profile.
        Pers Individ Differ. 2001; 30: 311-320
        • Eronen M.
        • Angermeyer M.C.
        • Schulze B.
        The psychiatric epidemiology of violent behaviour.
        Soc Psychiatry Psychiatr Epidemiol. 1998; 33: S13-S23
        • Moran P.
        The epidemiology of antisocial personality disorder.
        Soc Psychiatry Psychiatr Epidemiol. 1999; 34: 231-242
        • Harris G.T.
        The relationship between neuroleptic drug dose and the performance of psychiatric patients in a maximum security token economy program.
        J Behav Ther Exp Psychiatry. 1989; 20: 57-67
        • Kazdin A.E.
        Treatments for aggressive and antisocial children.
        Child Adolesc Psychiatr Clin N Am. 2000; 9: 841-858
        • Kunz M.
        • Yates K.F.
        • Czobor P.
        • Rabinowitz S.
        • Lindenmayer J.P.
        • Volavka J.
        Course of patients with histories of aggression and crime after discharge from a cognitive–behavioral program.
        Psychiatr Serv. 2004; 55: 654-659
        • Reeves R.R.
        • Struve F.A.
        • Patrick G.
        Auditory and visual P300 evoked potentials do not predict response to valproate treatment of aggression in patients with borderline and antisocial personality disorders.
        Clin EEG Neurosci. 2005; 36: 49-51
        • Reid W.H.
        • Gacono C.
        Treatment of antisocial personality, psychopathy, and other characterologic antisocial syndromes.
        Behav Sci Law. 2000; 18: 647-662
        • Timmerman I.G.
        • Emmelkamp P.M.
        The effects of cognitive–behavioral treatment for forensic inpatients.
        Int J Offender Ther Comp Criminol. 2005; 49: 590-606
        • Haller J.
        • Toth M.
        • Halasz J.
        The activation of raphe serotonergic neurons in normal and hypoarousal-driven aggression: A double labeling study in rats.
        Behav Brain Res. 2005; 161: 88-94
        • Haller J.
        • Horvath Z.
        • Bakos N.
        The effect of buspirone on normal and hypoarousal-driven abnormal aggression in rats.
        Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31: 27-31
        • Fu Q.
        • Heath A.C.
        • Bucholz K.K.
        • Nelson E.
        • Goldberg J.
        • Lyons M.J.
        • et al.
        Shared genetic risk of major depression, alcohol dependence, and marijuana dependence: Contribution of antisocial personality disorder in men.
        Arch Gen Psychiatry. 2002; 59: 1125-1132
        • Goodwin R.D.
        • Hamilton S.P.
        Lifetime comorbidity of antisocial personality disorder and anxiety disorders among adults in the community.
        Psychiatry Res. 2003; 117: 159-166